New drug cocktail shows promise for aggressive breast cancer

NCT ID NCT03090165

First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 18 times

Summary

This study tests a combination of two drugs, ribociclib and bicalutamide, in people with advanced triple-negative breast cancer that has a specific marker (androgen receptor). The goal is to see if this combo can shrink tumors or stop them from growing. About 37 participants will receive the treatment, and researchers will monitor side effects and how well the cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Michigan State University

    Lansing, Michigan, 48910, United States

  • Penn State Cancer Institute

    Hershey, Pennsylvania, 17033, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

  • University of Illinois Cancer Center

    Chicago, Illinois, 60612, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

  • University of Wisconsin

    Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.